WuXi AppTec : Chemistry - 2022 Investor Day

2 0 2 2 Wu X i A p p Te c I n v e s t o r D a y

WuXi Chemistry:

A Global Leading CRDMO

Minzhang Chen, Ph.D.

Co-CEO

						CDMO				CMO
	CRO
Target									Commercial
Hit	Lead	Preclinical	Phase I	Phase II	Phase III
to Hit	to Lead	to PCC	Manufacturing

3 Business Growth Engines

Small Molecule Chemistry	Drug Product	New Modalities
Medicinal Chemistry｜Custom Synthesis｜	Pre-formulation｜Formulation Development｜	Oligonucleotides｜Peptides｜Monomers｜
Library Synthesis｜Catalog｜Discovery Process	Manufacturing｜Packaging｜Labeling｜	Linkers｜Conjugates
Chemistry｜Process Chemistry｜Manufacturing	Distribution

Global Platform, Global Talents

		2022 H1
16 global sites	24,137 employees	2,014 clients worldwide

2

CRDMO business model drives sustainable high growth

3

"R" 28%↑[2]

"D" 42%↑[2]

"M"34%↑[2]

4

349,704 compounds

5,485 compounds "R+"

99[1]

1,627Preclinical & Phase I

39[1]

288 Phase II

8[1]

52 Phase III

8[1]	[1]	number of molecules were moved to next stage and kept
43Commercial		in WuXi Chemistry within past 12 months
[2]	increase rate vs. the number of end of 2021 June

Number of Compound Delivered by WuXi Chemistry C"R"DMO

+28%

+38%

355,189

278,105

201,516

2019.07-2020.06

2020.07-2021.06

2021.07-2022.06

5